Physician

Manuel Castro-Borobio, M.D.

According to 2025 Medicare claims, Manuel Castro-Borobio, M.D. (NPI: 1164788022) practices infectious disease in the Marietta, GA market, with the plurality of this provider's patient population coming from Cobb, GA. This provider's primary affiliated billing organization is INFECTIOUS DISEASE SERVICES OF GEORGIA PC (NPI: 1831236728; TIN: 73-1711534) and primary practice location at 30076-3880.

Castro-Borobio's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 380 traditional Medicare patients, billed 201,349 HCPCS/CPT codes, and received $913,604 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,129 prescription claims across 177 beneficiaries totaling $680,199 in drug costs, led by Biktarvy (Bictegrav/Emtricit/Tenofov Ala). DME data shows 25 claims. Open Payments data shows 27 records totaling $466. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $45,166 to $680,199. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $17,846 to $7,302.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	137	37,134	$73,475
2018	455	201,565	$900,575
2019	534	276,126	$1,285,807
2020	450	344,674	$1,332,961
2021	416	328,993	$1,485,752
2022	479	349,217	$1,120,063
2023	412	274,145	$970,460
2024	380	201,349	$913,604

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	45	481	$45,166
2016	20	371	$268,794
2017	43	229	$167,139
2018	136	408	$131,878
2019	185	931	$316,293
2020	175	971	$361,644
2021	149	795	$314,602
2022	187	904	$428,258
2023	199	1,006	$565,895
2024	177	1,129	$680,199

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	39	$72,313
2022	N/R	N/R	N/R
2023	N/R	25	$23,128
2024	N/R	25	$23,674

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	142	157	$99
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	165	743	$97
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	180	762	$61
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	67	1,295	$48
36415	Insertion of needle into vein for collection of blood sample	69	218	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	70	2,100	$280,861
Dovato	Dolutegravir Sodium/Lamivudine	21	630	$64,927
Vibativ	Telavancin Hcl	16	85	$46,122
Daptomycin	Daptomycin	27	178	$18,681
Ertapenem	Ertapenem Sodium	11	86	$7,077

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$19,718
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	12	$3,956

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	27	$466	ViiV Healthcare Company
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Manuel Castro-Borobio, M.D.?

Tedicare shows public-source Medicare data for Manuel Castro-Borobio, M.D. (NPI 1164788022), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Manuel Castro-Borobio, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Manuel Castro-Borobio, M.D.?

Manuel Castro-Borobio, M.D. is linked to INFECTIOUS DISEASE SERVICES OF GEORGIA PC (billing NPI 1831236728) in the available physician profile data.

Does Manuel Castro-Borobio, M.D. have Open Payments data?

Manuel Castro-Borobio, M.D. has 27 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.